Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abuse Deterrence: US Exclusivity Update May Ride User Fee Coattails

Executive Summary

CDER's Woodcock suggests exclusivity rules outdated for abuse-deterrent technology development, and Rep. Griffith takes it to mean legal changes are needed.

You may also be interested in...



Opioid Packaging: Is Non-Inferiority Enough For A New Claim?

Industry exec suggests new packages need be merely no worse than the classic amber vial to gain a claim, but US FDA says packaging intended to fight abuse should be better.

Opioids: Senate Wants Mandatory Prescriber Training; Can FDA Make It Work?

Appropriations bill report includes language stating that it is 'imperative' the agency take all steps necessary to require opioid prescriber training.

Final Generic Abuse-Deterrent Opioids Guidance Coming This Year

US FDA says it expects to finalize guidance by November, but more research is needed with generic development questions lingering.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel